Top 50 Biotechnology Startup Investors in Sweden in January 2026

Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

Almi Invest is Sweden’s most active early-stage venture capital firm, investing in scalable startups across Sustainability, Industry, Tech, and Life Science.We invest from pre-seed to Series A, always co-investing with independent private investors to accelerate innovation and long-term success. Our portfolio spans sustainable solutions,industrial innovation, deep tech, SaaS, and life science, supporting startups that drive economic and environmental progress.With €430 million under management and over 1,000 investments since 2009, we have backed leading companies like MIPS, Tobii, and Neo4j, with notable exits to Google, Apple, Microsoft, and Qlik.Beyond capital, we offer engaged ownership, providing strategic guidance, active board participation, and access to an extensive investor network.Almi Invest is part of the Almi Group and is funded by the European Regional Development Fund, Almi AB, and regional partners.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Welcome to Navigare Ventures. We invest in transformational early-stage companies at the frontier of science and technology.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Novo Holdings is a holding company specializing in life science investors with a focus on creating long-term value.

We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.

Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

We help great minds unleash their full potential!

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

EIR Ventures is a new Life Science Venture Group in the Nordics.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.

Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

LU Holding is a Lund University’s investment company.

FARO is an Argentina company over 10 years of experience in the development and operation of integrated projects in the agribusiness sector. All projects FARO own position it as a reference and leader both locally and internationally.Among his various projects, FARO operates the largest tree planting pecan nut Latin America, with projection tobecome the largest southern hemisphere and one of the largest in the world. This project is structured under different vehicles, including Alto Pecan stands, the first real estate development of nautical fields planted with pecan nut Latin America, located in Villa Paranacito, Entre Ríos . Another project is AgroConsortium, productive trust for the production and marketing of cereals and oilseeds in leased farms located in different productive areas in Argentina and potentially in the region. Finally, thanks to the expertise acquired in agribusiness, FARO developed his own business model for productive land conversion. Its aim is to position rural properties whose productive potential is not reflected in the price and complement the cycle with the economic use of land in intensive production, short and medium term.Since 2006, the Investor Group is a strategic partner OMBU FARO for all investment portfolios development ventures related to agribusiness, that focus on supply both local and international markets.

Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.

Länsförsäkringar is a Swedish group of public insurance companies.

Andreas is working on a service that will connect people, time and places on the web. He also works as an independent consultant helping other startups with product strategy, technical infrastructure, scalability and recruiting as well as financial companies (venture capital and private equity) with technical due diligence and in other advisorroles.He was CTO at Spotify from the launch of the company in August 2006 until November 2009. Before that he worked at Stardoll as an engineer and project manager.

Noaber Ventures invests in initiatives that bring social transformations using information technology.

I Love Lund is a venture capital firm.The firm seeks opportunities to invest in pre-seed rounds

FBG Invest

Scientifica Venture Capital offers private equity and venture capital investment services for Italy based startups and firms.

GU Ventures build businesses out of groundbreaking ideas that help shape a better tomorrow. Our passionate team of company builders, financial experts, IP and legal talent ensure success for our companies.

Fibonacci Growth Capital is a venture capital investment firm.

Value creation for Healthcare & Life Sciences Ventures through capital, expertise, international network.

Mikael Lonn is an Angel Investor.

Ferd er et familieeid investeringsselskap som er eid av femte og sjette generasjon Andresen.

Bonnier Capital is the investment division of the Bonnier Group. Since 2016, we invest in promising companies in structurally growing industries and have become a reliant investment partner to companies and funds of various sizes.

Pär Gellerfors

We're a traditional non-VC making data driven decisions from the heart.We fund innovation through supporting entrepreneurs that have a passion to create a market disrupting enterprises whilst making a noticeable difference in one, if not multiple of the Sustainable Development Goals set by the UN.Using AI through a dedicated data drivenprocess, we're identifying opportunities and selecting our startups and entrepreneurs based on thousands of data points from a network of partners across the globe.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.

Josefin Landgård is the Founder and CEO of Mantle. Previously she served as the Co-Founder and COO at KRY back in March 2014 to September 2018.

Joyance Partners is the first venture fund supporting companies that deliver Delightful Moments derived from science - a new, transformative cycle of human experience that we see as one of the greatest investment opportunities in decades.

SmiLe Inject Capital is an angel investment company to focus exclusively on early-stage life science companies.

Annexstruktur is a venture capital firm that provides investments to companies.

We partner with founders to transform unseen scientific discoveries into future breakthroughs, jointly moving businesses, people, and the world forward.

Klimatet Invest is to create long-term value growth by investing relatively early in idea companies with good growth potential in cleantech and at the same time contributing to a more sustainable society.

Pan-european early-stage deep-tech VC

Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.

LifeArc Ventures a self-funding medical research charity that invests in Seed and Series-A stage Biotech and Healthtech companies.

Jens Mogensen is an Angel Investor.

Inter IKEA Group's aim is to secure continuous improvement, development, expansion and a long life of the franchising operation.